home about us pipeline investors research news events careers sitemap contact© 2008 BionorImmuno, Inc. All rights Reserved
NEWS 2010
2010 2009 2008 2007 2006 2005 2004 2003
Vacc-4x Shows Response Seven Years after Inoculation. <<Back EMBARGO FOR 1230 CEST Thurs 22 July Researchers Present Findings Today at the XVIII International AIDS Conference, Vienna Austria Bionor Immuno's Therapeutic HIV Vaccine Candidate Vacc-4x Targeting Conserved Domains of HIV Produce Immune Response Seven Years after Inoculation (Vienna, Austria, 22 July 2010) Researchers at Oslo University Hospital and Bionor Pharma's subsidiary, Bionor Immuno AS today presented results from a recently conducted re-vaccination study at Norway's largest hospital, using Vacc-4x, the company's furthest advanced HIV-vaccine candidate. Twenty six of the forty HIV-patients from the 2002/03 phase IIa study were followed-up and re-vaccinated during the period January 2010-June 2010. The data from 22 Vacc-4x primary responders was presented today in Vienna, Austria at the XVIII International AIDS Conference as a “late breaker” poster titled “Longterm proliferative CD4+ and CD8+ T cell memory detected 7 years after intradermal immunizations against short HIV Gag p24-like peptides targeting dendritic cells.” The abstract number is LB17810. The 22 patients were studied prior to a voluntary “re-boost” of Vacc-4x. Results from the reboost of the 26 patients are expected in August / September. "The Vacc-4x immunization technology using short peptide analogues to conserved viral protein domains has shown not only development of surprisingly long-term immunological memory T cells in these immunocompromised patients, but also that viral sequences changes during intermittent treatment interruptions were negligible," said Professor Dag Kvale, Oslo University Hospital, co-author of the study. “Given this new data, and because Vacc-4x is comprised of 4 modified peptides that target conserved domains of the HIV p24 protein, we are especially optimistic about our ability to control HIV,” said Birger Sørensen, CEO, Bionor Immuno. “The research indicates that the vaccine is stimulating an immune response seven years after injection, which is, in itself, unprecedented in HIV. But we know we have more work to do.” Vacc-4x has completed an international phase IIb placebo controlled, double-blind, multi-national trial in volunteers with HIV who stopped daily antiretroviral treatment. Data from this study is expected in September/October. Rolf Henning Lem, CFO +47 23 01 09 61 +47 97 74 88 45 rhl@bionorpharma.com Birger Sørensen, EVP and Head of Vaccines +47 404 07 565 +47 23 01 09 60 bs@bionorpharma.com USA David Sheon +1202 547-2880 adc@bionorimmuno.com
HOME ABOUT US PIPELINE RESEARCH INVESTORS NEWS SITEMAP CONTACT US EVENTS CAREERSBionor Immuno AS, a subsidary of Bionor Pharma ASA was established on July 14th 2000 as a spin off from the R&D on immune based therapies that until then had been performed by its sister company, Bionor AS. Both companies are located at the Telemark Biomedical Centre, Skien, Norway together with two of its development partners AS Telelab and Mericon AS.